|
|
|
|
| Delivery remains RNA therapeutics' biggest hurdle—especially beyond the liver. In this Advancing RNA Live, Anna Rose Welch is joined by experts exploring nonviral, non-LNP delivery solutions pushing the boundaries of coding and noncoding RNA. Hear what makes these novel vehicles promising and learn how companies are tackling the scientific and operational challenges that stand in the way. Don’t miss this deep dive into the future of RNA drug delivery innovation. |
|
|
|
|
At the start of the latest Advancing RNA panel discussion, expert Tiffany Lucas outlines the biggest changes happening at the FDA and speculates on how these shifts may impact CBER’s ongoing work in the ATMP/mRNA space. |
|
|
|
By H. Gunter and T. Mercer, The University of Queensland | A poorly designed mRNA sequence can create ongoing difficulties during downstream clinical development and manufacture. Let's take a closer look at strategies and design software that you can employ. | |
|
|
|
On this week's Business of Biotech, Thomas Levenson, MIT professor and author of So Very Small: How Humans Discovered The Microcosmos, Defeated Germs — And May Still Lose The War Against Infectious Disease talks about what he learned in the writing of So Very Small, how cultural and political forces shape scientific progress, and what it means for drug developers, public health officials, and patients everywhere. |
|
|
|
|
|
| Solvent-Free Purification Of D84-mer Oligonucleotide | Poster | Cytiva | Discover a solvent-free process using Capto PlasmidSelect and Capto Q ImpRes resins. They enable high-purity, scalable purification of long oligonucleotides, achieving more than 95% of full-length product purity. |
|
|
|
|
|
|
.png){kind=logo}
